Use of granulocyte colony-stimulating factors (G-CSF) post-ASCT has been associated with faster neutrophil engraftment in several prospective randomized trials [8, 9], with lower incidences of infection, reduced treatment with broad-spectrum antibiotics, days of hospitalization and treatment costs, and better clinical outcomes [10–13]. The gene discussed is CSF3; the disease is infection.